Irwin Goldstein
Urology · San Diego, CANPI 1215058441
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (37.3%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 40 manufacturers reported payments, led by Coloplast at 27.9% of the total. Among urology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 385 payments — averaging $463.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Coloplast$50K
- AMAG Pharmaceuticals, Inc.$34K
- Verity Pharmaceuticals Inc.$21K
- Pfizer$20K
- Upjohn US 1 LLC$15K
- Endo Pharmaceuticals Inc.$11K
- plus $28K from 34 others
Across 57 payments — averaging $3224.85 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$95K
- AMAG Pharmaceuticals, Inc.$71K
- Ipsen Innovation$12K
- Endo Pharmaceuticals Inc.$5K
- Pfizer$780
What the payments were for
- Consulting fees$66,63637%
- Speaking & faculty fees$59,96534%
- Travel & lodging$38,56722%
- Food & beverage$9,1835%
- Education$4,1062%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$178,457 in reported general payments places this provider in the 95th percentile of 1,324 urology providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JatenzoTestosterone Undecanoate | 21 | $18,098 |
| TlandoTestosterone Undecanoate | 16 | $15,258 |
| Estradiol | 37 | $5,634 |
| Testosterone | 26 | $4,634 |
| IntrarosaPrasterone (Dhea) | 17 | $4,500 |
| Estradiol (Twice Weekly)Estradiol | 35 | $2,788 |
| ProgesteroneProgesterone, Micronized | 89 | $2,206 |
| Testosterone Cypionate | 42 | $1,883 |
| Cabergoline | 16 | $1,712 |
| Levothyroxine Sodium | 42 | $223 |
| Anastrozole | 27 | $150 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Clarus Therapeutics Inc.Jatenzo | $5,488 | $18,09821 claims |
| Antares Pharma, Inc.Tlando | $344 | $15,25816 claims |
| AMAG Pharmaceuticals, Inc.Intrarosa | $34,239 | $4,50017 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,324 urology providers in California.
Other urology in San Diego
- Elward CrawfordSan Diego$849K
- Roger SurSan Diego$356K
- Emily ColeSan Diego$261K
- Seth BechisSan Diego$260K
- Tung-Chin HsiehSan Diego$240K
- Mark PeSan Diego$226K
- Manoj MongaSan Diego$154K
- Stephen FreedlandWest Hollywood$1.9M
- Arie BelldegrunLos Angeles$1.8M
- Mihir DesaiLos Angeles$1.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.